多发性骨髓瘤的免疫治疗

Immunotherapy of multiple myeloma

多发性骨髓瘤（MM）的发生、发展与机体免疫功能缺陷密切相关.传统的化疗多注重于直接杀伤MM细胞,患者接受化疗后不良反应较大,生活质量较低.更为重要的是,绝大多数MM患者接受化疗后,疾病进展或复发.免疫治疗因其导致的不良反应少,靶向性强,而有望成为治愈MM的新型治疗手段.笔者拟就有关MM免疫治疗的细胞免疫治疗、体液免疫治疗、放射免疫治疗及免疫调节剂4个方面的现状及进展进行综述.

The onset and development of multiple myeloma （MM） are closely related to immunodeficiency of the host.Traditional chemotherapy eradicates MM cells directly through inducing cell death,resulting in many side effects and poor quality of life.However,MM remains incurable and will eventually become resistant to chemotherapy,and progression or relapse is inevitable.The immunotherapy represents a novel therapeutic approach with few side effects and good targeting capability.This article reviews literatures on clinical data evaluating 4 major immunotherapeutic approaches for MM,including cellular immunotherapy,humoral immunotherapy,radioimmunotherapy and immunomodulation.